Breast cancer (HER2 positive, unresectable) - trastuzumab emtansine (after trastuzumab & taxane) [ID603]

NICE in development [GID-TAG350] Anticipated publication date:

Documents

A list of downloadable documents created during development

Breast cancer (HER2 positive, unresectable) - trastuzumab emtansine (after trastuzumab & taxane): appraisal consultation

Breast cancer (HER2 positive, unresectable) - trastuzumab emtansine (after trastuzumab & taxane): final scope

Breast cancer (HER2 positive, unresectable) - trastuzumab emtansine (after trastuzumab & taxane): final matrix

Breast cancer (HER2 positive, unresectable) - trastuzumab emtansine (after trastuzumab & taxane): response to consultee and commentator comments on the draft scope and provisional matrix (post-referral)

Breast cancer (HER2 positive, unresectable) - trastuzumab emtansine (after trastuzumab & taxane): equality impact assessment - scoping

Breast cancer (HER2 positive, unresectable) - trastuzumab emtansine (after trastuzumab & taxane): draft scope - (pre referral)

Breast cancer (HER2 positive, unresectable) - trastuzumab emtansine (after trastuzumab & taxane): provisional matrix - (pre referral)

Get involved